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Conclusions: VEGF/R inhibitor was found to synergize with chemotherapeutics.
This effect was most pronounced with the anti-metabolite class.
Statement of Translational Relevance
It is controversial whether inhibitors of VEGF and its receptor (collectively termed VEGF/R inhibitors) interact synergistically with chemotherapy. To address this question, we tested for significant therapy and patient subgroup interactions with VEGF/R inhibitors among patients with advanced solid disease treated on phase I protocols within a single department. This analysis identified a synergistic interaction between chemotherapy agents, most notably with the anti-metabolite class. These results provide an actionable hypothesis for future clinical and benchtop research. In addition, future analyses of aggregated phase I trials may serve as a useful adjunct in the increasingly rapid development of targeted agents in order to identify promising therapy combinations and patient subgroups to test in phase III trials.
Introduction
Inhibitors of vascular endothelial growth factors (VEGF) and their receptors (VEGFR) have been extensively studied in numerous cancer types. Bevacizumab was one of the first VEGF inhibitors and was found to be efficacious in metastatic nonsmall cell lung cancer and colorectal cancer through the pivotal ECOG studies E4599(1, 2) and E3200(3), respectively. Conversely, administration of bevacizumab failed to extend overall survival in other cancer types including breast(4) and pancreatic(5). Following these mixed signals, the FDA approved a number of more recent drugs with anti-VEGFR activity, including sorafenib in hepatocellular(6) and renal (7) , sunitinib in renal (8) and neuroendocrine (9) , and pazopanib for renal (10) cancer. However, despite the growing number of VEGF and VEGFR (VEGF/R) inhibitors, there remains little consensus on the optimal patient subgroups and therapy combinations.
To improve clinical efficacy, bench-top and clinical research has focused on combining these agents with other therapeutics, most notably chemotherapy.
Numerous hypotheses have arisen to support synergistic interactions between these two agents. One such hypothesis is that inhibition of angiogenesis produces transient and long-term hemodynamic phenomena by modifying vasculature architecture resulting in a net improvement in chemotherapy mass transport (11, 12) . Chemotherapy cytotoxicity directed towards cancer vasculature has also been proposed to synergize with VEGF/R inhibitors (13-15). However, the proposed synergy between these agents has not been extensively validated. Although many phase III trials have combined VEGF/R inhibitors with chemotherapy, most of these 6 trials were conducted with disparate chemotherapy classes on different patient subgroups thereby complicating a fair assessment of these factors (5, [16] [17] [18] .
We sought to test the hypothesis that chemotherapy agents synergize with VEGF/R inhibitors by assessing the probability of clinical benefit in patients enrolled in phase I trials at the Department of Investigational Therapeutics at MD Anderson Cancer Center. In addition, we further tested whether patient diagnoses or mutational status predicted for response with VEGF/R inhibitors.
Patients and Methods

Patient Characteristics
Following Institutional Review Board approval, 1,498 patients were included in this 
Treatment and evaluation
After meeting individual trial inclusion criteria, patients were initiated on phase I trials judged to be clinically appropriate by the attending physician. criteria (19, 20) and reported as the best achieved response. All patients receiving PET imaging also received a co-registered CT scan, from which RECIST criteria measurements were obtained. In the event that a patient was treated on more than one phase I trial, the protocol that yielded the best response was analyzed.
Tissue samples and molecular analyses
All pathology analyses were conducted on archival formalin-fixed, paraffin- 
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The outcome of interest was clinical benefit, which was defined as stable disease ≥6 months or objective evidence of partial or complete response via RECIST criteria (19, 20) . Multivariate odds ratios (ORs) were generated via logistic regression. First, an overall OR for clinical benefit was calculated associating each the factor of interest/chemotherapy with frequency of clinical benefit among the entire cohort.
Then for each factor of interest/chemotherapy, two odds ratios (ORs) for achieving clinical benefit were calculated within a multivariate model: one for patients treated with VEGF/R inhibitors (OR with VEGF/R) and another for patients who did not receive these inhibitors (OR without VEGF/R). To compare these two ORs, an interaction term was included in the multivariate model: (chemotherapy/factor of interest)×(VEGF/R). We took significant interaction terms (interaction P<0.05) to suggest effect modification (either synergy or antagonism) with VEGF/R inhibitor use. Supplementary Appendix 2 illustrates example calculations for synergistic and antagonistic interactions. Other adjusted covariates included: number of prior systemic therapies, number of agents utilized during the best phase I protocol, age, gender, race, favorable/unfavorable diagnoses, year of treatment initiation, and chemotherapy class. Favorable and unfavorable diagnoses were defined as ≥40% or <40% proportion of clinical benefit among all patients, respectively (as listed in Table 2 footnote).
Continuous variables were compared via Student's t-test, while categorical variables were compared using chi-squared and Fisher exact tests. Recursive partitioning analysis was conducted to separate patients treated with VEGF/R inhibitors into strata based on frequency of clinical benefit. All P-values were two-9 sided when appropriate with significance considered at the P<0.05 level. Analyses were conducted using SAS ver. 9.3 and JMP ver. 10 (both SAS Institute Inc., Cary NC).
Results
Patient Characteristics
Baseline and treatment characteristics stratified by VEGF/R inhibitor treatment are summarized in Table 1 
Chemotherapy and VEGF/R response
The frequency of clinical benefit among all patients within this study who received chemotherapy was 23%. Among the entire cohort, chemotherapy use was not associated with a higher probability of clinical benefit (OR=1.0 [95% CI 0.8- 
Mutation status and VEGF/R response
The most common genetic mutation detected among the entire cohort was in TP53 (Fig. 2) . Analysis of specific KRAS mutations revealed point mutations at G12 (n=64, 81% of tested) and G13 (n=10, 13%) to be most prevalent.
There was no significant difference in the frequency of known activating KRAS 
Diagnoses and VEGF/R response
Frequency of overall response varied greatly between diagnoses (Table 2).
Clinically favorable diagnoses within this study (≥40% clinical benefit among all patients) were thymic (75% response), thyroid (70%), adrenal (46%), nonsquamous head and neck cancer (44%), unknown primaries (44%), and small bowel (40%). In contrast, clinically unfavorable diagnoses (<20% clinical benefit among all patients) were lower bowel (19%), lung (18%), cutaneous (18%)(other than melanoma), mesothelioma (17%), gastroesophageal (17%), uterine (17%), and central nervous system (11%). (Fig. 3) 
Discussion
This is to our knowledge the first study to aggregate patient-level data from multiple phase I trials to explore the interaction of chemotherapy with VEGF/R inhibitors.
Significant findings include the association between VEGF/R inhibitors with higher frequency of clinical benefit among all patients, a finding that held on multivariate analyses and remained consistent across different VEGF/R inhibitor categories.
Chemotherapy use was not associated with higher probability for clinical benefit among all patients; however, concomitant chemotherapy use with a VEGF/R inhibitor was associated with significantly higher OR for clinical benefit, suggesting a synergistic interaction. Among chemotherapy classes, the highest degree of synergy with VEGF/R inhibitors was exhibited by anti-metabolites followed by 18) . Resistance to these inhibitors may reflect an underlying hypoxic drive, which is either not affected by or produces significant compensatory mechanisms when treated with VEGF/R inhibitors (22, 23) . Specific to pancreatic cancer is the hypoxic desmoplastic stroma, which may represent a microenvironment less sensitive to angiogenesis inhibition (24, 25) . However, It is important to note that reduced OR for clinical benefit with VEGF/R inhibitor use may not reflect an antagonistic effect, but may instead result from exclusion of more efficacious therapies. For example, melanoma diagnosis and BRAF mutations were associated with lower OR for clinical benefit with VEGF/R inhibitors. This finding may reflect the opportunity cost of BRAF mutated melanomas patients not enrolled on BRAF inhibitor trials due to their enrollment on trials with VEGF/R inhibitors (21, 26) . This hypothesis is supported by sensitivity analyses removing melanoma patients treated with BRAF inhibitors from the regression model. In these analyses both the diagnosis of melanoma and BRAF mutation status did not significantly interact with VEGF/R inhibitor use (both P>0.05).
In contrast, patients with TP53 mutations exhibited a higher rate of clinical benefit with VEGF/R inhibitors, a finding observed in our previous work (27) .
Possible explanations include a role of TP53 mutations in promoting vascularization. This hypothesis is supported by clinical studies associating this mutation with increased vessel density within clinical studies (28) and neovascularization in xenograft models (29) . With regard to other mutations, patients exhibiting MET mutation and amplifications appeared to have opposite albeit non-significant interactions with VEGF/R inhibitors (Fig. 2) . Analyzing specific mutation sites revealed the most common MET alteration to be N375S (60%), which has been suggested to be an inactivating mutation/polymorphism (30) . As such, the observed differences in clinical benefit between MET mutations and alterations may be explained by the function of this predominate alteration (Fig. 2) . Similarly NRAS and KRAS also exhibit analogous functions, but appear to have different (once again, non-significant) interactions with VEGF/R inhibitors. Unfortunately, give the unknown activity of NRAS mutations presented here, it is difficult to interpret this finding. Given the limited number of patients exhibiting specific gene mutations, further analysis of mutation interaction with VEGF/R inhibitors is warranted.
There are several limitations that must be considered. First, many VEGFR inhibitors target multiple receptor tyrosine kinases (31, 32) . Although, our analysis stratifying by VEGF/R inhibitor class did not reveal significant differences between classes, we cannot exclude the contributions of off-target effects. We regret to report that due to the ongoing nature of many of these trials, we are unable to disclose investigational agent identity. However, we present a list of NCT number of all trials included (Supplementary Appendix 1) . Second, as specific attending physicians selected the most appropriate trial for each patient, there was non-random pairing of patients and systemic agents. Although we attempted to control for baseline differences through multivariate analyses, statistical manipulations must be considered a poor substitute for adequate randomization. Also, as patients were 0/4 (0%) Frequency (percent proportions) displayed for all variables *Defined as favorable histology in multivariate analyses (≥40% rate of clinical benefit) within entire cohort which includes both VEGF/VEGFR inhibited and non-inhibited § Defined as unfavorable histology in multivariate analyses (≤20% rate of clinical benefit) within entire cohort which includes both VEGF/VEGFR inhibited and non-inhibited
